Related Experiment Video

Updated: Mar 17, 2026

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K

[IMPROVING THE EFFICACY OF THERAPY FOR PATIENTS WITH MYOCARDIAL INFARCTION COMPLICATED BY CIRCULATORY FAILURE]

V M Zhenilo, A Z Avsaragova, Z T Astakhova

    Eksperimental'Naia I Klinicheskaia Farmakologiia
    |July 27, 2016
    PubMed

    Insights

    Remaxol improves treatment for myocardial infarction patients with acute cardiac insufficiency. This drug speeds up hemodynamic stabilization, enhances heart function, and reduces arrhythmia and hyperhomocysteinemia risks.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Internal Medicine

    Context:

    • Myocardial infarction (MI) with acute cardiac insufficiency presents significant treatment challenges.
    • Conventional thrombolytic therapy may not fully address hemodynamic instability and myocardial dysfunction.
    • Hyperhomocysteinemia is a risk factor for thrombotic complications in acute myocardial infarction.

    Purpose:

    • To evaluate the effectiveness of adding remaxol to conventional treatment for acute myocardial infarction (MI) patients.
    • To assess remaxol's impact on systemic hemodynamics, myocardial contractility, and cardiac arrhythmias.
    • To determine remaxol's role in managing hyperhomocysteinemia and reducing thrombotic risks in MI patients.

    Summary:

    • A study involving 126 acute myocardial infarction patients with acute cardiac insufficiency compared conventional therapy to therapy including remaxol.
    • The remaxol group received daily intravenous remaxol post-thrombolytic therapy for 3-5 days, with monitored vital signs.
    • Remaxol administration resulted in faster hemodynamic stabilization, improved myocardial contractility, reduced arrhythmias, and lowered hyperhomocysteinemia.

    Impact:

    • Remaxol inclusion significantly enhances treatment outcomes for myocardial infarction patients with acute cardiac insufficiency.
    • This therapeutic approach accelerates recovery, mitigates cardiac arrhythmias, and lowers the risk of thrombosis and thromboembolism.
    • Remaxol offers a promising adjunct therapy for improving cardiovascular health and reducing complications post-MI.

    More Related Videos

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

    Published on: April 17, 2021

    9.2K
    Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

    Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

    Published on: May 26, 2023

    1.7K

    Related Concept Videos

    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    511
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    584
    Acute Coronary Syndrome IV: Interprofessional Care01:28

    Acute Coronary Syndrome IV: Interprofessional Care

    IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
    405
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    470
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    725
    Myocarditis III: Medical Management01:14

    Myocarditis III: Medical Management

    Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
    309